Loading, Please Wait...
MIAMI, May 06, 2019 (GLOBE NEWSWIRE) -- Progressive Care Inc. (OTCQB: RXMD), a personalized healthcare services and technology company, today announced that it has launched a cold chain integrity pilot program with Frostime, LLC to ensure that all medicines are delivered to the patient at the prescribed temperature range.
The Cold Chain Integrity Pilot Program will be one of the first of its kind for last mile pharmaceutical logistics. The program is designed to allow pharmacies who do local deliveries to patients at home with the first ever temperature controlled device that tracks the internal temperature throughout the journey. PharmCo RX will be the first pharmacy to incorporate Frostime, LLC’s cooling technology (FrostMed) into the delivery system which is beneficial for common cold chain medications like insulin, vaccines, and antibiotics.
Currently, there is no regulatory requirement from Pharmacies to validate cold chain temperatures during the delivery process. From the time the medicine leaves PharmCo in South Florida and arrives to the patient, the company will be able to monitor and track the medicine’s temperature exposure on the FrostMed mobile app, to ensure that the medicine and cooler are remaining at a consistent temperature level.
“Inaccuracies in medicine temperatures have been a long-time issue in our industry,” said Shital Mars, CEO of Progressive Care Inc. “We are excited to be the first pharmacy to initiate this program with Frostime, LLC’s patented state of the art technology and to develop trust and integrity in the pharmaceutical cold chain logistics space.”
The Company chose to work with Frostime, LLC for this pilot program for a number of reasons including the ease of use, data integrity, cost, logistical support and technological advancement. Frostime, LLC’s FrostMed product also is environmentally friendly in that it does not use single use plastics, Styrofoam or other non-durable materials, or toxic chemicals. The liquid CO2 is captured from various industrial sources thus not increasing the CO2 concentration in the atmosphere.
“It is a privilege for us to partner with such a progressive and forward thinking organization as Progressive Care Inc, to launch our first project aimed at pharmacy last-mile logistics,” said Rob Saul, CEO of Frostime, LLC. “Progressive Care’s market will help us validate our product in an extreme weather environment and collect data enabling us to enhance our patented technology. With over 6,000 deliveries per month, Progressive Care is a perfect fit for our technology as a validation partner.”
FrostMed was developed to replace the current inconvenient, inefficient, expensive and sometimes dangerous cooling solutions used in the last mile transport of heat sensitive medicines, blood products, antibiotics, vaccines, hormones and specimens.
About Frostime, LLC
Founded in 2014, Frostime, LLC has worked tirelessly to create a portable cooling device that help overcome portable cooling challenges faced in a number of different industries. With the upcoming official launch, set for Summer 2019, Frostime, LLC. will provide this new portable cooling solution to clients ranging from military and medical logistics to the outdoor sportsman.
For more immediate updates on the company’s media coverage, connect with Progressive Care and PharmCo on social media:
About Progressive Care Inc.
Progressive Care Inc. (OTCQB: RXMD), through its PharmCo, LLC, is a South Florida health services organization and provider of prescription pharmaceuticals, compounded medications, provider of tele-pharmacy services, the sale of anti-retroviral medications, medication therapy management (MTM), the supply of prescription medications to long-term care facilities, and health practice risk management.
Cautionary Statement Regarding Forward-Looking Statements
Statements contained herein that are not based upon current or historical fact are forward-looking in nature and constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such forward-looking statements reflect the Company’s expectations about its future operating results, performance, and opportunities that involve substantial risks and uncertainties. These statements include but are not limited to statements regarding the intended terms of the offering, closing of the offering and use of any proceeds from the offering. When used herein, the words “anticipate,” “believe,” “estimate,” “upcoming,” “plan,” “target,” “intend” and “expect” and similar expressions, as they relate to Progressive Care Inc., its subsidiaries, or its management, are intended to identify such forward-looking statements. These forward-looking statements are based on information currently available to the Company and are subject to a number of risks, uncertainties, and other factors that could cause the Company's actual results, performance, prospects, and opportunities to differ materially from those expressed in, or implied by, these forward-looking statements.